KKR announced it will acquire Integer Holdings for $5.7 billion in cash, removing the medical device contract manufacturer from public markets in a transaction expected to close by year-end. The deal values Integer at a premium to its recent trading range and marks KKR's latest move into healthcare services infrastructure.
Integer operates as a contract development and manufacturing organization for medical devices, producing components and finished systems for cardiology, neuromodulation, and surgical applications. The company generated $1.48 billion in revenue over the trailing twelve months, with operating margins near 14 percent. Integer's client base includes large-cap medical device OEMs that prefer to outsource manufacturing complexity in regulated categories. KKR will inherit seven manufacturing sites across the U.S., Europe, and Latin America, plus a portfolio of approximately 2,400 active customer programs.
The transaction continues a documented trend: private equity firms are paying substantial multiples for contract manufacturing businesses in sectors where regulatory moats and client switching costs create predictable cash flows. Integer's CDMO model relies on multi-year supply agreements with device makers who face FDA approval burdens if they shift vendors. That stickiness is especially valuable as medical device innovation accelerates in minimally invasive therapies and neuromodulation, both areas where Integer holds technical certifications and cleanroom infrastructure. KKR will likely pursue bolt-on acquisitions to consolidate fragmented manufacturing capacity, using Integer's compliance framework as the integration platform.
For Integer's existing equity holders, the all-cash structure eliminates execution risk and provides immediate liquidity. For KKR, the acquisition adds a durable revenue base in a sector where labor, materials, and capital intensity are passed through to customers under cost-plus contracts. The firm has deployed similar playbooks in healthcare services—buying regulated infrastructure businesses, optimizing procurement and working capital, then scaling through acquisitions. Integer's management indicated the deal provides capital to expand capacity in high-growth categories without quarterly earnings pressure.
Allocators should track KKR's post-close capital deployment into Integer's manufacturing footprint, expected to begin in Q1 2027. The firm will likely announce capacity expansions or adjacent acquisitions within twelve months of deal closure, targeting neuromodulation and cardiac rhythm management suppliers. Competing CDMOs in adjacent categories—orthopedic implants, drug delivery devices—will face stepped-up M&A attention as PE firms replicate the Integer thesis. Publicly traded peers with similar profiles include Enovis (surgical devices CDMO) and Paragon 28 (orthopedic contract manufacturing), both of which saw volume increases on the Integer news.
Integer's exit leaves fewer pure-play public CDMO equities in the medical device sector. The premium KKR paid—reportedly 16-18x forward EBITDA based on sell-side estimates—sets a new floor for private valuations in regulated contract manufacturing.